J.P. Morgan is out with its report today on Medtronic MDT, maintaining Neutral.
In a note to clients, J.P. Morgan writes, "Our $41 December 2011 price target values Medtronic at 11.0x our CY12 EPS forecast. This is a modest discount to the company's current NTM multiple of 11.6x, and compares to the large-cap MedTech average of 13.0. We believe that this valuation level is appropriate given the current business challenges the company faces and its long-term growth profile, which we peg at 3-4% and 6-7% on the top
and bottom line, respectively. With better upside opportunities elsewhere, we assign MDT shares our Neutral rating."
At the time of posting, shares of MDT were trading pre-market at $38.75, down 0.67% from Tuesday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in